Onsdag 30 Oktober | 09:25:15 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2026-02-19 14:00 Bokslutskommuniké 2025
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-16 08:00 Kvartalsrapport 2025-Q2
2025-04-24 - Årsstämma
2025-04-24 08:00 Kvartalsrapport 2025-Q1
2025-02-19 14:00 Bokslutskommuniké 2024
2024-10-23 - Kvartalsrapport 2024-Q3
2024-07-16 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning BIOT 1.60 SEK
2024-04-25 - Kvartalsrapport 2024-Q1
2024-04-25 - Årsstämma
2024-02-15 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-17 - Kvartalsrapport 2023-Q2
2023-04-28 - X-dag ordinarie utdelning BIOT 1.60 SEK
2023-04-27 - Kvartalsrapport 2023-Q1
2023-04-27 - Årsstämma
2023-02-15 - Bokslutskommuniké 2022
2022-11-02 - Kvartalsrapport 2022-Q3
2022-07-19 - Kvartalsrapport 2022-Q2
2022-04-29 - X-dag ordinarie utdelning BIOT 1.55 SEK
2022-04-28 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-11 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-07-16 - Kvartalsrapport 2021-Q2
2021-04-29 - X-dag ordinarie utdelning BIOT 1.50 SEK
2021-04-28 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-12 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-06-05 - X-dag ordinarie utdelning BIOT 0.00 SEK
2020-06-04 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-07 - Bokslutskommuniké 2019
2019-11-07 - Extra Bolagsstämma 2019
2019-11-05 - Kvartalsrapport 2019-Q3
2019-07-16 - Kvartalsrapport 2019-Q2
2019-04-25 - X-dag ordinarie utdelning BIOT 1.50 SEK
2019-04-24 - Kvartalsrapport 2019-Q1
2019-04-24 - Årsstämma
2019-02-07 - Bokslutskommuniké 2018
2018-11-06 - Kvartalsrapport 2018-Q3
2018-07-16 - Kvartalsrapport 2018-Q2
2018-04-27 - X-dag ordinarie utdelning BIOT 1.40 SEK
2018-04-26 - Kvartalsrapport 2018-Q1
2018-04-26 - Årsstämma
2018-02-08 - Bokslutskommuniké 2017
2017-11-02 - Kvartalsrapport 2017-Q3
2017-07-18 - Kvartalsrapport 2017-Q2
2017-04-28 - X-dag ordinarie utdelning BIOT 1.25 SEK
2017-04-27 - Årsstämma
2017-02-09 - Bokslutskommuniké 2016
2016-11-10 - Kvartalsrapport 2016-Q3
2016-08-11 - Kvartalsrapport 2016-Q2
2016-04-29 - X-dag ordinarie utdelning BIOT 1.00 SEK
2016-04-29 - X-dag bonusutdelning BIOT 0.25
2016-04-28 - Kvartalsrapport 2016-Q1
2016-04-28 - Årsstämma
2016-02-11 - Bokslutskommuniké 2015
2015-10-30 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-04-29 - X-dag ordinarie utdelning BIOT 0.75 SEK
2015-04-28 - Kvartalsrapport 2015-Q1
2015-04-28 - Årsstämma
2015-02-12 - Bokslutskommuniké 2014
2014-10-30 - Kvartalsrapport 2014-Q3
2014-08-14 - Kvartalsrapport 2014-Q2
2014-04-29 - X-dag ordinarie utdelning BIOT 0.60 SEK
2014-04-28 - Kvartalsrapport 2014-Q1
2014-04-28 - Årsstämma
2014-02-13 - Bokslutskommuniké 2013
2013-10-25 - Kvartalsrapport 2013-Q3
2013-08-15 - Kvartalsrapport 2013-Q2
2013-04-26 - X-dag ordinarie utdelning BIOT 0.50 SEK
2013-04-25 - Årsstämma
2013-04-25 - Kvartalsrapport 2013-Q1
2013-02-12 - Bokslutskommuniké 2012
2012-10-26 - Kvartalsrapport 2012-Q3
2012-08-17 - Kvartalsrapport 2012-Q2
2012-04-27 - X-dag ordinarie utdelning BIOT 0.40 SEK
2012-04-26 - Kvartalsrapport 2012-Q1
2012-04-26 - Årsstämma
2012-02-09 - Bokslutskommuniké 2011
2011-10-26 - Kvartalsrapport 2011-Q3
2011-08-17 - Kvartalsrapport 2011-Q2
2011-04-28 - X-dag ordinarie utdelning BIOT 0.25 SEK
2011-04-27 - Årsstämma
2011-04-27 - Kvartalsrapport 2011-Q1
2011-02-10 - Bokslutskommuniké 2010
2010-10-26 - Kvartalsrapport 2010-Q3
2010-08-13 - Kvartalsrapport 2010-Q2
2010-04-30 - X-dag ordinarie utdelning BIOT 0.20 SEK
2010-04-29 - Kvartalsrapport 2010-Q1
2010-02-11 - Bokslutskommuniké 2009
2009-10-27 - Kvartalsrapport 2009-Q3
2009-08-14 - Kvartalsrapport 2009-Q2
2009-04-28 - X-dag ordinarie utdelning BIOT 0.20 SEK
2009-04-27 - Kvartalsrapport 2009-Q1
2009-04-27 - Årsstämma

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Biotage är verksamt inom bioteknik. Bolaget tillhandahåller lösningar inom kromatografi, organisk syntes och provberedning. Bolaget har verksamhet på global nivå, främst koncentrerat till Europa, Nordamerika och Asien och en stor del av projekten bedrivs även i samarbete med övriga aktörer inom nämnd marknad. Kunderna återfinns inom vård och omsorg, samt inom livsmedelsindustrin.
2023-07-17 14:00:00

April – June

  • Net sales amounted to SEK 409 (395) million, an increase of 3.4 percent and an organic* decrease of 14.0 percent.
  • Operating profit amounted to SEK 53 (93) million and adjusted* to SEK 78 (98) million.
  • The operating margin was 12.9 percent (23.4) and adjusted to 19.1 percent (24.7).
  • EBITA* amounted to SEK 64 (100) million and adjusted to SEK 90 (105) million.
  • The EBITA margin* amounted to 15.8 percent (25.2) and adjusted to 22.0 percent (26.5).
  • Profit after tax amounted to SEK 34 (57) million.
  • Earnings per share were SEK 0.49 (0.87) before and after dilution.
  • Cash flow from operating activities decreased to SEK 51 (88) million.
  • Net cash* as of June 30 was SEK 226 (224) million.
  • On April 28, Maja Nilsson informed that she is leaving the position as CFO.
  • On June 1, Biotage completes the acquisition of Astrea Group Holdings Company Ltd ("Astrea"). As part of the transaction 13,954,103 ordinary shares were issued in June.

January – June

  • Net sales amounted to SEK 769 (781) million, a decrease of 1.5 percent and an organic* decrease of 13.4 percent.
  • Operating profit amounted to SEK 106 (189) million and adjusted* to SEK 149 (199) million.
  • The operating margin was 13.8 percent (24.2) and adjusted to 19.4 percent (25.5).
  • EBITA* amounted to SEK 125 (203) million and adjusted to SEK 169 (213) million.
  • The EBITA margin* amounted to 16.3 percent (26.0) and adjusted to 21.9 percent (27.3).
  • Profit after tax amounted to SEK 77 (129) million.
  • Earnings per share were SEK 1.13 (1.95) before and after dilution.
  • Cash flow from operating activities decreased to SEK 62 (145) million.
  • On March 9, it was announced that Lars Bäckman, Chief Legal Officer, will retire and leave Biotage in September 2023.
  • On April 28, Maja Nilsson informed that she is leaving the position as CFO.
  • On June 1, Biotage completes the acquisition of Astrea Group Holdings Company Ltd ("Astrea"), which was announced on 15 February 2023. As part of the transaction 13,954,103 ordinary shares were issued in June.

Message from the CEO
On June 1, Biotage completed the acquisition of Astrea Bioseparations. Astrea contributed to our record sales of SEK 409 million in the second quarter of the year. We are now very much looking forward to building this successful company further that, like Biotage, has the customer in focus.

The acquisition of Astrea further strengthens Biotage for the future. With our shared expertise and resources, we can create a world-leading chromatography platform that covers both small and large molecules. Astrea delivered convincingly strong double-digit growth in June, in line with our own high internal expectations. In addition, Astrea strengthens the group’s aftermarket business, which accounted for a total of 63% of sales in the second quarter, exceeding our target of 60%. Our service business is also developing strongly, with double-digit growth figures, thanks to the previously acquired ATDBio.

The underlying business in Scale Up continues to develop with strong growth, we still have some way to go before we see the same sales volumes as during the pandemic. We are also actively working to broaden our business in China and to run our aftermarket business with local partners. During the period, customers continued to decommission stocks and showed caution regarding capital purchases, resulting in reduced system sales. However, thanks to implemented price increases, we are seeing a positive quarterly development for our gross margin and adjusted EBITA (which were 62% and 22%, respectively, in the quarter). We have also seen how supply chain challenges have decreased during the quarter, lead times have been shortened, and freight prices have been reduced.

The fact that Biotage is now a company with a global presence and a diversified product portfolio helps make us less vulnerable. We are never passively facing challenges, but prioritizing resources where there are prerequisites for success. A new sales record was set again in the second quarter for our largest geographical market in terms of sales, Americas, which grew by 16%. Thanks to our investment in Biologics & Advanced Therapeutics through the Astrea acquisition, we also saw growth in EMEA.

Of our three customer focus areas, both Red Tech and Blue & Green Tech continued to grow during the quarter. Four of our six product areas grew during the quarter. Diagnostics, which includes our oligonucleotide business, showed double-digit organic growth and both Analytical Testing and Water & Environmental Testing continued to grow. Thanks to the Astrea acquisition, Biologics & Advanced Therapeutics also grew significantly.

We continue to develop new solutions with a strong focus on our customers. We have launched the Biotage® PeptiRen-96 well plates, which, together with our Biotage® Extrahera™ sample preparation system, can streamline the peptide purification workflow with a low solvent consumption. We are combining existing solutions in a new application that improves the process for our customers, while at the same time increasing Biotage’s current revenue in an attractive and growing niche with a positive future. A clear example of how customer focus builds value for ourselves, our customers and other stakeholders.

With the introduction of a new security pack for our Biotage® Selekt product family for flash purification, we have also taken further steps in our digitalization strategy and of our customer journey. It provides complete, built-in, industry-standard encryption for secure remote control and monitoring of Biotage® Selekt systems, protecting customers’ valuable information and scientific research from data breaches.

After an intensive first half of the year, we are now looking forward to continuing the good cooperation we have started with our new colleagues at Astrea. At the same time, our global organization continues to work with a high level of commitment to improve gross margins. Today we are a strong company, with the aim of putting Swedish life sciences on the world map. It gives us confidence for the rest of the year!